Search Results

MC# 13-10
A Phase III, Randomized, Double-blind, Controlled Study of Cabozantinib (XL184) vs Placebo in Subjects with Hepatocellular Carcinoma Who Have Received Prior Sorafenib

MC# 14-06
A Multicenter, Phase I/Ib, Open-Label, Dose-Escalation Study of ABBV-399, an Antibody Drug Conjugate, in Subjects with Advanced Solid Tumors

MC# 14-08
A Multicenter, Phase I/Ib, Open-Label, Dose-Escalation Study of ABT-165, a Dual Variable Domain Immunoglobulin in Subjects with Advanced Solid Tumors

MC# 14-28
A Phase Ib Dose-Escalation and Phase IIa Study of TRC105 in Combination with Pazopanib in Patients with Advanced Soft Tissue Sarcoma

MC# 14-30
Phase II Study Of Combined Targeted P53 Gene Therapy (SGT-53) Plus Gemcitabine/Nab-Paclitaxel For Treatment Of Metastatic Pancreatic Cancer

MC# 14-36
A Phase I/II Study Exploring the Safety, Tolerability, and Efficacy of Epacadostat in Combination with Durvalumab in Subjects with Selected Advanced Solid Tumors

MC# 15-01
A Randomized, Double-Blind, Placebo-Controlled Phase II/III Trial of Vigil™ Augmented Autologous Tumor Cell Immunotherapy in Subjects with Stage III/IV Ovarian Cancer in Clinical Complete Response following Surgery and Primary Chemotherapy

MC# 15-15
Randomized Phase IIb Trial of VIGIL™ (bi-shRNAfurin and GMCSF Augmented Autologous Tumor Cell Immunotherapy) for Ewing’s Sarcoma

MC# 15-24
A Phase 2 Study of Vigil™ Augmented Autologous Tumor Cell Immunotherapy in combination with Nivolumab PD-1 inhibitor for Patients with Advanced Non-Small Cell Lung Cancer

MC# 15-25
A Pilot Study of Vigil™ Augmented Autologous Tumor Cell Immunotherapy in Combination with Pembrolizumab PD-1 inhibitor for Patients with Advanced Melanoma

MC# 15-31
: A Phase Ib/II, Open-label, Multicenter, Dose-escalation and expansion Trial of Intratumoral SD-101 in Combination With Pembrolizumab in Patients With Metastatic Melanoma

MC# 15-32
Phase II, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

MC# 15-36
A Phase I/II Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of VT-464 in Patients with Advanced Breast Cancer

MC# 16-03
A Phase Ib Study of an Immunotherapeutic Vaccine, DPX-Survivac with Low Dose Cyclophosphamide and Epacadostat (INCB024360) in Patients with Recurrent Ovarian Cancer.

MC# 16-06
Pilot Study of Durvalumab (MEDI4736) in Combination with Vigil™ in Advanced Breast Cancer

MC# 16-10
A randomized parallel group phase III trial of OSE 2101 as 2nd line after prior platinum-based chemotherapy failure or as 3rd line after platinum-failure and checkpoint inhibitor-failure, compared with standard treatment (docetaxel or pemetrexed) in HLA-A2 positive patients with locally advanced (IIIB) unsuitable for radiotherapy or metastatic Non-Small-Cell Lung Cancer.

MC# 16-12
Study Title: Phase I Trial of pbi-shRNA™ EWS/FLI1 Type 1 lipoplex (LPX) in Subjects with Advanced Ewing’s Sarcoma

MC# 16-14
A Phase I/Ib, Open-Label, Multicenter, Repeat-Dose, Dose-Selection Study of CPI-444 as Single Agent and in Combination with Atezolizumab in Patients with Selected Incurable Cancers

MC# 16-22
A Randomized, Open-Label, Multi-Center, International Phase II Study of TAS-114 in Combination With S-1 in Patients with Advanced or Metastatic Non-Small Cell Lung Cancer

MC# 16-28
A Multi-Center Open-Label Phase I/II Study of BGB324 in Combination with Erlotinib in Patients with Stage IIIb or Stage IV Non-Small Cell Lung

MC# 16-30
A Phase I/Ib Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Clinical Activity of Defactinib in Combination with Avelumab in Epithelial Ovarian Cancer

MC# 15-29
A Phase Ib, Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) Combined with Pembrolizumab in Subjects with Selected Hyaluronan High Solid Tumors

MC# 16-01
A Phase I, Open-label, Multiple-ascending Dose Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of MSB0011359C in Subjects with Metastatic or Locally Advanced Solid Tumors and Expansion to Selected Indications

MC# 16-02
A Four Part, Phase 1, Multi-center, Open-label Study of DKN-01 in Combination with Weekly Paclitaxel; Part A: A Dose-Escalation Study in Patients with Relapsed or Refractory Esophageal Cancer or Gastro-esophageal Junction Tumors; Part B: An Expansion Cohort in Patients with Relapsed or Refractory Esophageal Cancer or Gastro-esophageal Junction Tumors; Part C: An Expansion Cohort in Patients with Relapsed or Refractory Esophageal or Gastro-esophageal Junction Adenocarcinoma; Part D: An Expansion Cohort in Patients with Relapsed or Refractory Esophageal Squamous Cell Cancer

MC# 16-15
A First-in-Human Study of Repeat Dosing with REGN2810, a Monoclonal, Fully Human Antibody to Programmed Death – 1 (PD-1), as Single Therapy and in Combination with Other Anti-Cancer Therapies, in Patients with Advanced Malignancies